UNC REX Healthcare – Wake Radiology to set up medical imaging services

The shift that will occur due to elimination of hospital fees for imaging services is anticipated to reduce patient costs by nearly $7 million a year. UNC REX Healthcare, the private, not-for-profit health care system, recently announced that it has joined forces with Wake Radiology to expand specialized imaging services …

Sanofi & Regeneron Pharmaceuticals announce results for Dupixent study

Dupixent showed significant improvement in patients with acute chronic rhinosinusitis with nasal polyps as well as co-morbid asthma. A recently released report for Phase 3 trials of Dupixent has conclusively demonstrated that dupilumab in combination with corticosteroid nasal spray has the potential to improve chronic sinus disease. Besides this, the …

Novartis to pursue development of therapy for elevated Lipoprotein(a)

The company would be licensing the rights to develop as well as commercialize TQJ230 for targeted cardiovascular therapy If approved, the TQJ230 would be a first in class therapy specifically designed for elevated Lp(a) Novartis International AG (Novartis), a renowned Swiss pharmaceutical firm, has reportedly announced that it has decided …

Merck agrees to buy Immune Design to enhance immunotherapy portfolio

Merck & Co. has recently announced that it has agreed to acquire Immune Design in a deal valued at approx. $300 million, for boosting Merck’s vaccine pipeline and technology capabilities. Apparently, Immune Design had reduced its workforce by 18% last year and established a new lead candidate, after its previous …

BioSig Technologies conducts first human PURE EPTM System evaluation

The positive result positions the company well on delivering its strategic goals for 2019 and encourages the company to expand its evaluation efforts. BioSig Technologies, Inc., a US-based medical device company, recently announced that it has successfully conducted the first in-human cases using PURE EPTM System which is a proprietary …

U.S. Food & Drug Administration grants Fast Track Designation to ARS-1

ARS-1 can be used for rapid delivery of epinephrine with less hesitation during an allergic reaction when compared to the administration of epinephrine auto-injectors ARS Pharmaceuticals, Inc., the pharmaceutical company known for its contribution to the development of medicines that can prevent severe allergic reactions causing anaphylaxis, recently announced that …

Bausch Health acquires rights for preservative-free allergy eye drop

The EM-100 developed by Eton Pharmaceuticals would be the first ever preservative-free eye drop available in U.S. that can be used in allergic ocular itching. Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc, along with its parent company and Eton …

QIAGEN partners with Ares Genetics to strengthen AMR research

QIAGEN can use Ares Genetics’ Antimicrobial Resistance (AMR) database and use its expertise in bioinformatics to accelerate AMR research. QIAGEN N.V., the Netherlands-based provider of Sample to Insight solutions recently announced that it has signed a broad agreement with Ares Genetics that specializes in infectious disease diagnostics and therapeutics, to …

PRODIGY, developed by Medtronic for OIRD yields preliminary results

The study was aimed at developing and internally validating the PRODIGY score, which is an accurate OIRD risk assessment scoring tool. Medtronic plc, one of the largest medical technology, services and solutions companies in the world has recently announced that PRODIGY, a study to monitor people at risk of opioid-induced …

Cancer diagnostics firm Burning Rock closes $125.5m Series C funding

The company wants to establish a global leader in tumor precision medicine brand and also lead China’s cancer genetic testing industry. Chinese biotech company Burning Rock has reportedly completed a $125.5 million (850 million yuan) Series C funding round which was led by GIC, the sovereign wealth fund of Singapore. …